AstraZeneca and Amgen report positive Phase 3 results for Tezspire in eosinophilic esophagitis treatment

AstraZeneca and Amgen's drug Tezspire met primary endpoints in a late-stage trial for eosinophilic esophagitis, demonstrating significant reduction in esophageal inflammation and dysphagia. This success provides a positive catalyst for AstraZeneca's pipeline following recent development challenges.